Lack of clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: A retrospective analysis

Journal of Clinical Gastroenterology

Volumn 47, Issue 2, 2013, Pages 188-192

  Neff, Guy W ^a   Jones, Michael ^b   Jonas, Mark ^c   Ravinuthala, Ravi ^c   Novick, David ^d   Kaiser, Tiffany E ^a   Kemmer, Nyingi ^a  

^a Tampa General Medical Group   (United States)

^b Tri State Gastroenterology Associates   (United States)

^c Greater Cincinnati Gastroenterology Associates   (United States)

^d Digestive Specialists Inc   (United States)

Author keywords

Clostridium difficile; hepatic encephalopathy; rifaximin

Indexed keywords

ANTIDIARRHEAL AGENT; QUINOLONE; RIFAXIMIN;

ADULT; ARTICLE; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY HOSPITAL; DIARRHEA; DRUG SAFETY; FECES ANALYSIS; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; INCIDENCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; UNIVERSITY HOSPITAL; UPPER RESPIRATORY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; INCIDENCE; LATEX FIXATION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFAMYCINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84872904211     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318276be13     Document Type: Article

References (31)

1. Cordoba J, Minguez B. Hepatic encephalopathy. Semin Liver Dis. 2008;28:70-80.
2. Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57:1156-1165.
3. Maddrey WC. Role of antibiotics in the management of hepatic encephalopathy. Rev Gastroenterol Disord. 2005; 5(suppl 1):S3-S9.
4. Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy. 2008;28:1019-1032.
5. Bass NM. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther. 2006;25(suppl 1):23-31.
6. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med. 2001;161: 525-533.
7. Garey KW, Salazar M, Shah D, et al. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2008;42:827-835.
8. McFarland LV, Beneda HW, Clarridge JE, et al. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control. 2007;35:237-253.
9. Xifaxan [package insert]. Morrisville, NC: Salix Pharmaceuticals Inc.; 2010.
10. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity-a review. Chemotherapy. 2005;51(suppl 1):67-72.
11. Koo HL, DuPont HL. Current and future developments in travelers' diarrhea therapy. Expert Rev Anti Infect Ther. 2006;4:417-427.
12. DuPont HL. Biologic properties and clinical uses of rifaximin. Expert Opin Pharmacother. 2011;12:293-302.
13. DuPont HL, Jiang Z-D, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-812.
14. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846-848.
15. Berman AL. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea [letter]. J Clin Gastroenterol. 2007;41: 932-933.
16. Boero M, Berti E, Morgando A, et al. Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximine vs. vancomycin. Microbiol Med. 1990;5: 74-77.
17. Garey KW, Jiang Z-D, Bellard A, et al. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study [letter]. J Clin Gastroenterol. 2009; 43:91-92.
18. Neff G, Zacharias V, Kaiser TE, et al. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series. Liver Transpl. 2010;16:960-963.
19. Basu PP, Dinani A, Rayapudi K, et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol. 2010;3:221-225.
20. Tannous G, Neff G, Kemmer N. Therapeutic success of rifaximin for Clostridium difficile infection refractory to metronidazole and vancomycin. Case Rep Gastroenterol. 2010;4:404-409.
21. Johnson S, Schriever C, Patel U, et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe. 2009;15:290-291.
22. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2011;9:CD004610.
23. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-1081.
24. Mullen KD, Poordad F, Rossaro L, et al. Long term efficacy and survival in patients treated with the gut-selective antibiotic rifaximin (550 mg BID) for the maintenance of remission from overt hepatic encephalopathy. J Hepatol. 2011;54(suppl 1): S49-S50.
25. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol. 2010;105:106-113.
26. Bolton RP. Clostridium difficile-associated colitis after neomycin treated with metronidazole. Br Med J. 1979;2:1479-1480.
27. Williams R, Bass N. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord. 2005;5(suppl 1):S10-S18.
28. Brigidi P, Swennen E, Rizzello F, et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother. 2002;14:290-295.
29. Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostri-dium difficile-associated disease. Antimicrob Agents Chemother. 2008;52:2403-2406.
30. Kokkotou E, Moss AC, Michos A, et al. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Antimicrob Agents Chemother. 2008;52:1121-1126.
31. Pedretti G, Calzetti C, Missale G, et al. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol. 1991;23:175-178.